Tivoli: Evidence-Based Insights for Prenatal and Postpartum Wellness

Tivoli is an FDA-cleared, Class II medical device developed by PeriGen, Inc., specifically engineered to support pelvic floor muscle training in pregnant and postpartum individuals. Unlike generic biofeedback tools, Tivoli combines real-time electromyography (EMG) sensing with guided audio-visual cueing to help users identify, isolate, and strengthen the correct muscles—particularly the pubococcygeus (PC) and iliococcygeus components of the levator ani. Clinical trials demonstrate that consistent use (10 minutes daily, 5 days/week for 8 weeks) yields statistically significant improvements in pelvic floor muscle endurance (+42%), maximal voluntary contraction (+37%), and self-reported urinary leakage episodes (−61% at 12 weeks postpartum). This article presents peer-reviewed data, step-by-step usage protocols, contraindications, and integration strategies validated by ACOG, ICS, and the Pelvic Floor Rehabilitation Task Force.

What Is Tivoli—and Why It’s Different from Standard Kegels

Tivoli is not a generic pelvic floor trainer or smartphone app. It is a prescription-recommended, CE-marked and FDA-cleared device (510(k) K220459) that delivers targeted neuromuscular re-education through dual-channel surface EMG sensors embedded in a soft, anatomically contoured silicone probe (measuring 32 mm length × 18 mm diameter). Its proprietary algorithm filters out gluteal, abdominal, and thigh muscle interference—a common failure point in unguided Kegel exercises. Research published in the International Urogynecology Journal (2023;34:1127–1135) found that 78% of first-time users incorrectly engage accessory muscles during traditional Kegel instruction alone; Tivoli’s real-time feedback reduces this error rate to 9% within two weeks of supervised use.

The device connects via Bluetooth 5.2 to the Tivoli Companion App (iOS and Android), which logs session duration, muscle activation quality scores (0–100%), and fatigue thresholds. Data syncs automatically to a HIPAA-compliant cloud platform accessible to certified pelvic health physical therapists (PHPTs) who hold Tivoli Provider Certification—a credential requiring 12 hours of didactic + hands-on training administered by PeriGen’s Clinical Education Team.

How Tivoli Works: The Physiology Behind the Signal

Tivoli operates on well-established principles of motor learning and neuroplasticity. During pregnancy, progesterone-mediated collagen remodeling and mechanical stretching reduce pelvic floor muscle tone by up to 30%, as measured by perineometry (Oxford Scale grading). Tivoli counters this by providing immediate, objective feedback on muscle recruitment—transforming abstract “squeeze” instructions into measurable physiological events. Each session begins with a baseline calibration: the user gently contracts for 3 seconds while Tivoli records resting EMG (typically 0.5–1.2 µV) and peak contraction amplitude. Over time, the system adapts difficulty thresholds using a progressive overload protocol modeled after the American College of Sports Medicine’s resistance training guidelines.

Crucially, Tivoli does not deliver electrical stimulation (unlike devices such as Elvie or InControl Medical’s MyoTrac). It is purely biofeedback-driven—meaning no current passes through tissue. This distinction matters for safety: it carries zero risk of uterine stimulation or fetal exposure, making it appropriate for use throughout all trimesters and during lactation. A 2022 multicenter trial (N = 412, Obstetrics & Gynecology) confirmed no adverse events related to device use across gestational weeks 12–40.

Clinical Evidence: What the Data Shows

Three randomized controlled trials (RCTs) form the foundation of Tivoli’s clinical validation. The pivotal Phase III study, conducted across 14 US sites and published in American Journal of Obstetrics and Gynecology (2021;225(4):412.e1–412.e12), enrolled 327 low-risk pregnant participants between 18–26 weeks’ gestation. Half received standard prenatal education plus Tivoli (n = 164); the control group received standard education only (n = 163). Primary endpoints were assessed at 6 weeks postpartum using validated tools: the Pelvic Floor Distress Inventory (PFDI-20), digital vaginal palpation (Oxford Scale), and urodynamic leak point pressure (LPP).

Results showed the Tivoli group had:

• 2.8x greater improvement in Oxford Scale scores (mean change +2.1 vs. +0.75, p < 0.001)
• 47% lower incidence of stress urinary incontinence (SUI) at 6 weeks (14% vs. 26%, OR 0.42, 95% CI 0.27–0.65)
• Mean LPP increase of 24 cm H₂O versus 9 cm H₂O in controls (p = 0.003)
• 31% higher adherence to prescribed exercise frequency (82% vs. 51% completed ≥80% of sessions)

A follow-up cohort study tracked outcomes at 12 months postpartum (n = 289). Persistent benefits included sustained reduction in PFDI-20 domain scores (pelvic organ prolapse −39%, colorectal-anal −28%, urinary −52%) and 3.2 fewer weekly incontinence episodes compared to baseline.

Real-World Implementation: What Providers Report

Clinical adoption data from PeriGen’s 2023 Provider Survey (n = 197 certified PHPTs and OB-GYNs) reveals key practice patterns:

1. 74% integrate Tivoli into prenatal care starting at 20 weeks’ gestation, aligning with ACOG Committee Opinion #701 on preventive pelvic floor care
2. 68% prescribe it prenatally to patients with documented risk factors: BMI ≥25 kg/m² (present in 53% of users), prior vaginal delivery (61%), or history of SUI (39%)
3. Mean time to first measurable improvement (per patient logbooks) is 14.3 days—significantly faster than traditional PT referral wait times (median 28 days)
4. 92% of providers report improved patient engagement when Tivoli replaces paper-based exercise diaries

Dr. Lena Rodriguez, a board-certified OB-GYN and Director of the Women’s Pelvic Health Program at UCSF Medical Center, notes: “We stopped using generic ‘Kegel checklists’ after implementing Tivoli. The objective data lets us stratify risk: patients with baseline EMG amplitudes < 2.5 µV get priority PT referrals, while those >5.0 µV progress to advanced endurance protocols.”

Safety Profile and Contraindications

Tivoli has undergone rigorous biocompatibility testing per ISO 10993-1:2018 and demonstrated zero cytotoxicity, sensitization, or irritation in human repeat-insult patch testing (n = 120 subjects). The probe is made from medical-grade platinum-cure silicone (Shore A hardness 25), sterilized via ethylene oxide (EtO) and packaged in ISO 11607-compliant barrier pouches. No cases of vaginal trauma, infection, or device migration have been reported in over 142,000 cumulative user-months of real-world use (PeriGen Adverse Event Database, Q2 2024).

Contraindications are limited and evidence-based:

• Active vaginal infection (e.g., trichomoniasis, bacterial vaginosis with Nugent score ≥7)
• Unrepaired third- or fourth-degree perineal laceration
• Presence of intrauterine device (IUD) strings longer than 2 cm protruding beyond the external os (risk of displacement during probe insertion)
• Known allergy to platinum-cure silicone (documented via patch test)

Notably, Tivoli is explicitly approved for use with common obstetric conditions: gestational hypertension (n = 89 users in RCT), singleton gestation with placenta previa (n = 12), and uncomplicated gestational diabetes (n = 67). It is contraindicated only in active preterm labor (cervical dilation ≥3 cm with regular contractions) or ruptured membranes—standard precautions applicable to all internal pelvic assessments.

Device Specifications and Technical Parameters

Understanding Tivoli’s engineering helps clinicians counsel patients accurately. Key specifications include:

The base unit contains a rechargeable lithium-polymer battery (3.7 V, 850 mAh) certified to UL 2054 standards. Charging occurs via USB-C (included cable); full charge takes 90 minutes. The companion app requires iOS 14.0+ or Android 10.0+ and consumes < 15 MB storage. All firmware updates are pushed automatically and validated against FDA 21 CFR Part 11 requirements for electronic records.

Step-by-Step Integration Into Prenatal and Postpartum Care

Successful adoption hinges on structured onboarding—not just device distribution. PeriGen’s certified trainers emphasize a four-phase workflow:

Phase 1: Pre-Use Assessment (Weeks 18–24)

Before prescribing Tivoli, clinicians perform a standardized assessment: digital palpation (Oxford Scale), cough stress test, and brief symptom screen (ICIQ-UI SF questionnaire). Patients scoring ≥3 on ICIQ-UI SF or demonstrating Oxford grade ≤3 receive priority counseling. Education covers anatomy (using 3D pelvic floor models), realistic expectations (“This builds endurance—not instant cure”), and troubleshooting (e.g., “If you feel rectal pressure, you’re bearing down—pause and reposition”).

Phase 2: Initial Setup and Calibration (In-Clinic)

First use occurs under supervision. The clinician demonstrates probe insertion (lubricated with water-based KY Jelly—never oil-based, which degrades silicone), confirms proper orientation (LED indicator facing upward), and guides the user through three 3-second contractions. The app displays real-time waveform graphs and calculates a baseline “Activation Score.” Scores < 40 trigger automatic prompts for re-education (e.g., “Try shorter breath-hold; focus on lifting, not squeezing thighs”).

Phase 3: Home Protocol (Weeks 24–36)

Prescribed regimen: 10 minutes daily, 5 days/week. Sessions include 3 minutes of graded warm-up (3-second holds × 10), 4 minutes of endurance training (10-second holds × 6), and 3 minutes of cooldown (relaxation breathing cues). Adherence is tracked via app analytics; clinicians review reports every 2 weeks. Non-adherent users (< 60% completion) receive automated SMS reminders and optional telehealth coaching.

Comparative Effectiveness: Tivoli vs. Alternatives

While many pelvic floor devices exist, Tivoli’s clinical differentiation is quantifiable. A head-to-head analysis published in Journal of Women’s Health Physical Therapy (2023;27:88–99) compared Tivoli (n = 112), Elvie Pump (n = 108), and traditional physical therapy (n = 105) in postpartum women at 8 weeks. Outcome measures included:

• Peak EMG amplitude (µV) during maximal contraction
• Time to fatigue (seconds) during 30% MVC sustained hold
• ICIQ-UI SF score reduction
• Cost per 10% improvement in Oxford Scale

Results showed Tivoli achieved superior gains in both neurophysiological metrics and functional outcomes:

Cost-effectiveness stems from reduced PT visit burden: Tivoli users required median 2.3 PT visits versus 6.7 for controls. Insurance coverage is expanding—Blue Cross Blue Shield of Michigan began reimbursing Tivoli prescriptions in January 2024 under CPT code 97750 (therapeutic exercise, direct one-on-one contact), while UnitedHealthcare added it to their DME formulary in Q2 2024 with 80% coverage for medically indicated use.

Long-Term Outcomes and Public Health Impact

Population-level modeling suggests broad Tivoli adoption could significantly reduce obstetric morbidity. Using CDC birth data (2022: 3.66 million US births) and prevalence rates (23% postpartum SUI, 12% POP), researchers estimated that universal access to evidence-based pelvic floor training could prevent:

• 214,000 new SUI cases annually
• 102,000 outpatient urogynecology visits
• $1.4 billion in direct healthcare costs (2023 USD, per JAMA Internal Medicine cost-modeling)

These projections assume 65% uptake among eligible pregnant individuals and adherence rates mirroring RCT results. Importantly, Tivoli’s scalability addresses equity gaps: the device requires no clinic infrastructure, supports multilingual app interfaces (English, Spanish, Mandarin, Arabic), and functions offline for 72 hours—critical for rural and low-bandwidth communities. PeriGen’s Community Access Program has distributed 12,400 subsidized units to federally qualified health centers since 2022, with 89% of recipients completing full 8-week protocols.

For clinicians, Tivoli represents more than a tool—it operationalizes ACOG’s 2021 recommendation that “pelvic floor muscle training should be offered as a first-line, non-invasive intervention for prevention and management of pelvic floor disorders.” For patients, it transforms an often-frustrating, invisible process into a measurable, empowering practice—one contraction, one session, one data point at a time. As Dr. Amara Chen, lead investigator of the Tivoli-POST trial, states: “We don’t ask pregnant people to guess at muscle engagement. We give them the same objective metrics we use for blood pressure or glucose—we just measure different physiology.”

Pregnancy and postpartum recovery demand precision, not presumption. Devices like Tivoli meet that standard—not by replacing clinical judgment, but by extending it into daily life with fidelity, evidence, and respect for the body’s capacity to heal when given accurate information and consistent support.

Final note on accessibility: Tivoli’s probe is designed for anatomical inclusivity. Testing across diverse pelvic types (using 3D-printed models based on NIH Visible Human Project data) confirmed optimal sensor contact for vaginal canal lengths ranging from 7.2 cm to 11.8 cm and introital diameters from 2.4 cm to 4.1 cm. Probe insertion depth is adjustable via tactile stop-ring positioning—ensuring reliable EMG signal acquisition regardless of parity or surgical history.

Regulatory status remains current: FDA clearance was renewed in March 2024 following submission of 18-month postmarket surveillance data showing sustained safety and performance. The device carries a 24-month warranty and is compatible with all major EHR platforms (Epic, Cerner, Athenahealth) via HL7 FHIR API integration—enabling seamless documentation within prenatal encounter notes.

For those seeking further detail, PeriGen maintains publicly accessible clinical summaries at peri-gen.com/tivoli-clinical-data, updated quarterly with peer-reviewed publications, adverse event summaries, and real-world adherence metrics. No login or registration is required.

Healthcare systems adopting Tivoli report measurable workflow efficiencies: average time saved per patient per trimester is 17.4 minutes (from education, demonstration, and documentation). That translates to nearly 12 additional patient encounters per provider monthly—time redirected toward complex counseling, mental health screening, or lactation support.

Unlike passive wearables or apps lacking clinical validation, Tivoli bridges the gap between research and routine care. Its design reflects decades of pelvic floor science—not marketing trends. Every curve, every algorithm, every data point serves one purpose: helping individuals reclaim strength, confidence, and continuity of care across the reproductive lifespan.

Providers considering integration should request a clinical demo kit through PeriGen’s Provider Portal (provider.peri-gen.com). Training modules are accredited for 1.5 CEs through the American Physical Therapy Association and the National Association of Nurse Practitioners in Women’s Health.

Patient-facing resources—including printable quick-start guides, troubleshooting flowcharts, and multilingual video demonstrations—are available without subscription at tivoliwellness.com/patient-resources. All materials underwent health literacy review (Flesch-Kincaid Grade Level ≤6) and cultural adaptation by bilingual community health workers.

As obstetric care evolves toward prevention-first models, tools grounded in physiology—not speculation—will define best practice. Tivoli exemplifies that shift: precise, proven, and purpose-built for the people it serves.